Trump administration reclassifies cannabis in major shift that could expand scientific research
CNBC
Last updated: April 24, 2026
The Trump administration has initiated a move to reclassify cannabis under federal law, aiming to facilitate expanded scientific research into its medical applications. This action is distinct from efforts to legalize the substance.
- The proposed reclassification involves moving cannabis from its current Schedule I status under the Controlled Substances Act. Schedule I classifies drugs as having a high potential for abuse and no currently accepted medical use, significantly hindering research.
- By reclassifying cannabis, the administration anticipates that researchers will encounter fewer regulatory hurdles when investigating its potential therapeutic benefits for various medical conditions. This could lead to a better understanding of compounds like CBD and THC.
- The move is a procedural step that allows for more comprehensive studies, which are essential for determining the efficacy and safety of cannabis-based treatments. It does not constitute federal legalization of marijuana for recreational or medical purposes.
- The administration's focus is on enabling rigorous scientific inquiry, potentially paving the way for evidence-based medical guidance and treatments derived from cannabis.
